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CD28 is a receptor expressed on T cells
that regulates their differentiation after
antigen stimulation to long-term-survival
memory T cells. CD28 enhances T-cell
receptor signals and reduces expression
of CBL ubiquitin ligases, which nega-
tively control T-cell activation. In the ab-
sence of CD28 ligation during the pri-
mary stimulation, CBL levels remain high
and T cells fail to mount an efficient sec-
ondary response. CD28 associates with
p85, one of the regulatory subunits of
phosphoinositide-3-kinase (PI3K), but the
relevance of this interaction is debated.
We examined here the contribution of the
other ubiquitous PI3K regulatory subunit,
p85, in CD28 function. We describe that
p85 bound to CD28 and to CBL with
greater affinity than p85. Moreover, dele-
tion of p85 impaired CD28-induced intra-
cellular events, including c-CBL and
CBL-b down-regulation as well as PI3K
pathway activation. This resulted in defec-
tive differentiation of activated T cells,
which failed to exhibit an efficient second-
ary immune response. Considering that
p85-deficient T cells fail in recall re-
sponses and that p85 binds to and regu-
lates CD28 signals, the presented obser-
vations suggest the involvement of p85
in CD28-mediated activation and differen-
tiation of antigen-stimulated T cells.
(Blood. 2009;113:3198-3208)
Introduction
T-cell activation involves cooperation of signals triggered by the
T-cell receptor (TCR) and costimulatory molecules such as CD28.1
TCR engagement induces a cascade of early signals including
activation of Src family tyrosine kinases (TyrKs) pp56lck and
pp59fyn, which in turn phosphorylate the TCR chain and activate
the Syk family TyrK ZAP-70. ZAP-70 phosphorylates and associ-
ates numerous signaling molecules such as LAT and SLP-76,
which propagate the activation signal.2,3 These cascades elicit
expression of genes required for activation of hematopoietic cells,
and for T-cell expansion, effector function, and differentiation.4
CD28 binding contributes to T-cell activation by stabilizing
the immunologic synapse, by enhancing the magnitude and
duration of TCR-induced signaling cascades,5 and by inducing
long-term survival.6 CD28 is therefore necessary for optimal
activation of T cells, which become anergic (nonresponsive) in
the absence of CD28-derived signals.7,8 Although CD28 corecep-
tor function was initially described for CD4 T cells,9 it is also
required for optimal primary CD8 T-cell responses to most
pathogens as well as for their recall responses.10-13 CD28 can
evade the anergy program by inducing down-regulation of
Casitas B-lineage lymphoma b (CBL-b).14-17 CBL-b ubiquiti-
nates the p85 regulatory subunit of PI3K; this reduces p85
binding to CD28 and TCR, resulting in diminished PI3K
activation.18,19 CBL-b down-regulation, thus, is required for
optimal PI3K pathway activation, and in turn for Rac-induced
actin polymerization and immunologic synapse stability.20
c-CBL is another CBL family member that limits T-lymphocyte
activation.21 c-CBL exerts this action by down-regulating ZAP-70
TyrK, although c-CBL enhances PLC activation.21 c-CBL–
deficient mice show increased positive selection of T cells in
thymus as well as peripheral lymphoid hyperplasia.22-24 Whereas
changes in c-CBL expression after T-cell activation have not been
reported, this process causes an early reduction in CBL-b levels, an
event required for optimal T-cell activation.16,25,26 CBL-b levels
recover at later time points, contributing to trigger TCR trafficking
to the lysosomal compartment.27
Class I PI3K enzymes are formed by a p110 catalytic subunit
and a regulatory subunit; the p110 subunit catalyzes formation of
phosphatidylinositol (3,4)P2 and phosphatidylinositol (3,4,5)P3
after receptor stimulation. PI3Ks are classified as TyrK-controlled
class IA enzymes (p110, p110, and p110) that associate
p85-like regulatory subunits, and G protein–regulated class IB
PI3K, p110.28 In the case of class IA PI3K, 3 genes (pik3r1,
pik3r2, and pik3r3) and their alternative splice forms give rise to
5 regulatory subunits.28 Whereas p85 and p85 expression is
ubiquitous, p55, p55, and p50 expression is restricted to certain
tissues.28 PI3K binds to the TCR and to CD28 through p85, thereby
contributing to trigger T-cell activation, survival, and division28-35;
nonetheless, the contribution of PI3K to CD28-mediated signaling
remains incompletely understood.
We previously described that p85-deficient T cells exhibit a
moderately enhanced primary immune response.33 In the course of
these studies, we noticed that secondary responses in these mice
were defective. Considering that CD28 binds to p85 subunits,36-40
and that CD28 regulates recall T-cell responses,5-15 we examined
whether p85 contributes to mediate CD28 signals. We describe
that p85 associates with CD28, controls CD28-mediated signals,
and is required for efficient secondary immune responses.
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Methods
Mice and cDNA
p85/ mice, reported previously,33 were maintained in heterozygosis.
F5TCR (V11V4) transgenic (Tg) mice41 were provided by D. Kioussis
(Medical Research Council [MRC], London, United Kingdom). The CNB
ethics committee approved all animal studies. F5TCRTg mice were crossed
with p85/ mice; offspring were analyzed by polymerase chain reaction
(PCR) and flow cytometry to confirm the TCR transgene and correct MHC
expression. Mice were bred and maintained in specific pathogen-free
conditions in our animal facility; the CNB ethics committee approved all
studies. Recombinant hemagglutinin p85 (rHAp85) and rHAp85 were
donated by L. Williams (Chiron, Emeryville, CA) and J. Janssen (Heidel-
berg University, Heidelberg, Germany); we cloned both into the pEF-BOS
vector. Mutant forms of human p85 were cloned by PCR using primers
encoding HA peptide, including the appropriate coding sequence encom-
passing the SH3 domain (pEF-BOS HA-SH3) or SH2-SH2 region
(pEF-BOS HA-SH2-SH2). pSG5 p65PI3K, similar to the previously
described p65PI3K,42 was prepared by introducing a stop codon at residue
567 by point mutation.
Antibodies and reagents
Antibodies used for T-cell activation were hamster antimouse CD3
(145-2C11) and CD28 (37.51), mouse anti–human CD3 (UCHT1) and
CD28 (CD28.2), mouse anti–Armenian and -Syrian hamster IgG1 (G94-
56), mouse anti–Armenian hamster IgG (G192-1; all from BD Pharmingen,
San Jose, CA), and rabbit anti–mouse IgG (Fc-fragment specific; Jackson
Immunoresearch, West Grove, PA). For immunoprecipitation, protein A
Sepharose beads and the following antibodies were used: anti–mouse CD28
(37.51 [BD Biosciences, San Jose, CA] and M-20 [Santa Cruz Biotechnol-
ogy, Santa Cruz, CA]), anti–human CD28 (152-2E10; Biosource, Camarillo,
CA), anti-PI3K pan-p85 (Upstate Biotechnology, Lake Placid, NY),
anti-SH3 PI3K p85 (Upstate Biotechnology), anti–c-CBL (BD Bio-
sciences), anti–CBL-b (Santa Cruz Biotechnology), and anti-HA (Cova-
lence, Franklin, MA). We prepared an anti-p85 Ab using His-tagged
full-length murine p85; the Ab recognizes murine and human p85 and
not p85 (I.C. and A.C.C., in preparation). For Western blot, we used the
appropriate antibodies and developed them with enhanced chemilumines-
cence (ECL; GE Healthcare, Little Chalfont, United Kingdom). We
measured activity of PKC (protein kinase C) using anti–phospho PKC
(Thr514); PKB (protein kinase B; also termed Akt) using anti–phospho-
Akt (Ser473) and phospho-Akt (Thr308); p44/42 mitogen-activated protein
kinase (MAPK) using anti–phospho-p44/42MAPK (Thr202/Tyr204); and
p38 MAPK using anti–phospho-p38MAPK (Thr180/Tyr182; all from Cell
Signaling Technology, Beverly, MA).
Anti-PKC (C-20; Santa Cruz Biotechnology), -Akt1/PKB (Upstate Bio-
technology), -p42/44 MAPK, and -p38 MAPK (Cell Signaling) antibodies were
used to control loading. We analyzed the profile of tyrosine-phosphorylated
proteins using anti-PTyr antibody (4G10; Upstate Biotechnology). We also used
anti–CBL-b (G-1, C-20; Santa Cruz Biotechnology), anti–c-CBL (clone 17) and
anti–mouse Nedd4 (clone 15; both from BD Transduction Laboratories), anti–
human Nedd4 (Upstate Biotechnology), anti-actin (Sigma-Aldrich, St Louis,
MO), anti-HA(Covalence), and anti–pan-p85 antibody (Upstate Biotechnology).
Ly294002 was from Calbiochem (San Diego, CA).
Cell lines and transfections
Jurkat T cells were maintained in complete Dulbecco modified Eagle
medium (DMEM; BioWhittaker, Walkersville, MD) with 10% fetal bovine
serum (FBS; Sigma-Aldrich), 2 mM glutamine, 50 	M 2-mercaptoethanol,
and 100 U/mL penicillin/streptomycin. Cells (1.5 
 107) in 400 	L com-
plete medium were transfected by electroporation of 25 	g DNA using a
Gene Pulser (270 V, 950 	F; Bio-Rad, Hercules, CA). Cells were immedi-
ately transferred to 10 mL complete medium containing 50 	g/mL Z-VAD
(benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone) and assayed
after 36 hours, when fluorescence-activated cell sorting (FACS) or Western
blot analyses showed maximum expression of the transfected protein.
Spleen and lymph node cell suspensions were T-cell enriched by
depletion of B cells using mouse pan B (B220) Dynabeads (Dynal, Oslo,
Norway) followed by 2-hour incubation on plastic plates at 37°C to deplete
adherent cells, or using mouse T cell–negative isolation kits (Invitrogen,
Carlsbad, CA); T cells were more than 95% CD3 by FACS analysis (Epics
XL-MCL; Beckman Coulter, Hialeah, FL). For CD8 cells, T cell–enriched
suspensions were depleted of CD4 cells using Dynabeads. Primary T and
B cells were maintained in RPMI 1640 (BioWhittaker). Antigen-presenting
cells (APCs) were prepared by depleting T cells from spleen suspensions
with mouse pan-T (Thy1.2) Dynabeads.
Two-dimensional gel electrophoresis
Before activation, purified mouse or Jurkat T cells were incubated (2 hours)
in DMEM with 0.1% BSA (fraction V low endotoxin; Sigma-Aldrich), after
which cells were washed and resuspended in serum-free medium. For
activation, 5 to 10 
 106 cells were incubated with soluble anti-CD3anti-
CD28 Ab and cross-linked with secondary antibody as for in vivo T-cell
activation. Cells were lysed in CHAPS buffer (5% CHAPS, 20 mM
Tris-HCl, pH 8, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 137 mM NaCl,
5 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM EDTA,
1 	g/mL each aprotinin and leupeptin, and 2 nM okadaic acid; 4°C,
90 minutes). Extracts were immunoprecipitated with anti-p85 (1 	g/mL) or
CD28 (1 	g/mL; 4°C, 16 hours). Two-dimensional electrophoresis was
performed following standard procedures.
Statistical analyses
Statistical analyses were performed using StatView 512 (Calabasas, CA).
Gel bands were quantitated with ImageJ software (National Institutes of
Health [NIH], Bethesda, MD).
Online supplemental material
T-cell activation protocols, coupling of peptides to Actigel resin, in vitro
transcription translation, PI3K and PKB kinase assays, in vitro binding of
proteins to peptide columns, immunoprecipitation and Western blot assays,
TCR down-regulation analyses, flow cytometry assays, quantitative reverse-
transcription (RT)–PCR, and proliferation assays are available in Document
S1 (available on the Blood website; see the Supplemental Materials link at
the top of the online article).
Results
CD28 preferentially associates with p85
CD28 binds directly to the p85 regulatory subunit of PI3K.36-40
T cells express both of the ubiquitous p85 isoforms:  and ;33
however, the relative contribution of these subunits to CD28-
mediated signals has not been elucidated. We first examined the
relative abundance of p85 and p85 in Jurkat cells and wild-type
(WT) murine T cells. Because p85 and p85 have to be recog-
nized by distinct Abs, for comparison rather than Western blot
(WB), we performed quantitative RT-PCR (QRT-PCR) as p85
mRNA levels do correlate with p85 protein levels.43 Whereas the
ratio of p85/p85 was close to 1 in Jurkat cells, in murine T cells
p85 levels were approximately 15% those of p85 (Figure 1A).
We then examined p85-CD28 complex formation in Jurkat T cells
expressing similar levels of recombinant HA-tagged p85 or p85
(rHAp85 or rHAp85), which were approximately double that of
endogenous proteins (Figure 1B). We immunoprecipitated CD28, and
examined CD28-p85 association by WB detection with anti-HA anti-
body. Despite similar abundance of rHAp85 and rHAp85, CD28
bound a larger amount of p85 than p85 (Figure 1B).
We also examined endogenous CD28-p85 complex formation
in mouse T cells. As mentioned in Figure 1A, p85 mRNA levels
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were roughly one sixth those of p85; a moderate increase in p85
mRNA levels was found in approximately two-thirds of p85/
mice (Figure 1C, WB of a p85/ representative mouse with
enhanced p85 levels). We analyzed total WT T-cell extracts as
well as CD28 immunoprecipitates obtained from CD3CD28-
activated T cells in 2-dimensional gel electrophoresis. Whereas in
WT cells the p85 spot (the most acidic spot) represented
approximately 15% of the total p85, in CD28 immunoprecipitates
the p85 proportion was double, showing that relative to its
abundance p85 exhibits a greater affinity for CD28 (Figure 1D).
Similarly, in Jurkat cells, the human p85 right-most spot (the
more basic spot) was approximately 50% of the total signal in
whole extracts, and approximately 80% in CD28 immunoprecipi-
tates (Figure 1D).
We also compared the amount of endogenous p85 bound to
CD3 or CD28 receptors after T-cell activation by CD3, CD28, or
both. CD3 activation did not induce a significant association of
p85 to either CD3 or CD28 (Figure 1E). In contrast, CD28
activation induced the binding of p85 to CD28 but triggered as
well p85 binding to CD3 (Figure 1E), suggesting that CD28
stimulation is required to bring p85 into complex with CD3.
Finally, after CD3CD28 stimulation, a larger amount of p85
was found in CD28 immunoprecipitates, suggesting a greater
affinity of p85 for CD28 than for CD3 (Figure 1E). A similar
analysis performed with p85 showed that CD3 stimulation
triggered association of p85 to CD3, whereas CD28 activation
favored p85 association to CD28; a similar amount of p85 was
found in CD3 and CD28 receptors after CD3CD28 stimulation
(Figure 1E). Therefore, whereas p85 associates similarly with
both CD3 and CD28, p85 association to CD28 is greater than to
CD3, moreover, CD28 activation is required for association of
p85 to CD28 and to CD3. The analysis of CD28-bound p85 using
a pan-p85 Ab resembled the pattern of p85, supporting that CD28
binds greater levels of p85 than p85 (Figure 1E).
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Figure 1. CD28 preferentially associates with p85. (A) Ratio
of p85/p85molecules per nanogram of total mRNA determined
by QRT-PCR. (B) Jurkat cells transfected with control, rHAp85,
or rHAp85 vectors (36 hours), were activated via CD3CD28
(15 minutes). WB examined protein expression in total extracts,
extracts were also immunoprecipitated with anti-CD28 Ab, and
associated p85 was analyzed in Western blot (WB) using anti-HA
Ab (long and short exposure). (C) Number of p85 or p85
molecules per nanogram of total mRNA (from p85/ and
p85/ T cells) by QRT-PCR; each dot represents a mouse.
Western blot analysis of p85 in extracts of a representative mouse
(vertical line indicate a repositioned gel lane). (D) T cells from
p85/ and p85/ mice and Jurkat cells were activated as in
panel A. Total extracts or CD28 immunoprecipitates were re-
solved in 2-dimensional electrophoresis and analyzed in WB
using anti–pan-p85 antibody.  indicates the p85 spot (absent in
p85/ mice). The isoelectric point (pI) of mp85 was 5.74, and
the pIs were 5.96, 5.9, and 5.8 for mp85 and its phosphorylated
forms; the pI for hp85 was 6.03, and the pIs were 5.84, 5.77,
and 5.71 for hp85 and its phosphorylated forms. Graphs show
the mean plus or minus SD (n  3) of the  spot signal relative to
the combined signal for all spots (100%). (E) Jurkat cells were
activated as in panel B; WB shows the amount of p85 present in
CD3 or CD28 immunoprecipitates. Graphs show the mean signal
plus or minus SD (AU indicates arbitrary unit) of p85 bound to
CD3 or CD28. (F) cDNA encoding human (h) or mouse rp85 or
rp85 was transcribed/translated in vitro (rhp85 was fused to
GFP) in the presence of 35S-Met. Purified proteins were examined
by SDS-PAGE and autoradiography (top left). Sequence of the
hCD28 peptides; the dots represent the nonconserved amino
acids in mCD28 (H  P and P  A). In the bottom, p85 bound to
the different CD28 peptide columns analyzed by SDS-PAGE and
autoradiography. PDGFR (P) peptide was used as a positive
control; column with no peptide and mp85 was used as the
negative control. The histograms show the absolute binding of
each rp85 form to CD28 motifs (mean signal  SD in arbitrary
units [AU]) on the right, and rp85 relative binding to M peptides
and to P column (n  3). *t test, P  .05.
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To map p85-binding regions in the CD28 cytoplasmic tail, and to
quantify more accurately the amount of p85 and p85 bound to CD28,
we analyzed direct binding of purified in vitro transcribed and translated
p85 subunits to CD28 peptide columns. We selected 4 CD28 peptides
including theYMNM motif (M1), the C-terminalYRS region (M2), and
the Tyr-phosphorylated forms of these peptides (M1p, M2p; Figure 1F),
regions involved in CD28 binding to the p85 subunit.40
Translated murine and human 35S-Met–labeled p85 and p85
(h-p85 fused to GFP) were resolved in SDS–polyacrylamide gel
electrophoresis (PAGE) gels to measure p85 levels (Figure 1F),
equal amounts of purified p85 and p85 were loaded onto CD28
peptide columns, and we examined the binding of each isoform to
the columns. As negative controls we used columns with no-
peptide, as positive controls we used PDGF receptor (R) peptide
columns.42 p85 association to CD28 peptides was analyzed by
SDS-PAGE and autoradiography. Both p85 and p85 bound
slightly better to phosphorylated CD28 peptides, in addition, p85
bound slightly better to M1 peptides and markedly better to M2 and
M2p CD28 peptides, compared with p85 (Figure 1F). We also
compared p85 binding to CD28 peptides and to PDGFR peptide.
p85 binding to PDGFR was within the range of p85 and p85
binding to M1p peptide; binding to M2p was one-third to one-half
(human and mouse p85, respectively) that observed using PDGFR
peptide (Figure 1F, n  3). Although in these assays both p85 and
p85 bound better to M1p than to M2p columns, the scenario in
vivo might be distinct; deletion of the last 10 residues of CD28 (in
M2) reduces p85 binding and PI3K activity by 90%.40 The greater
affinity of p85 for the M2p columns explains the greater binding
of p85 to CD28 in vivo.
Lower PKB activation in p85-deficient cells
To determine whether the p85 regulatory subunits that bind to
CD28 upon T-cell activation exhibit p110-associated PI3K activity,
we transfected Jurkat cells with rHAp85 or rHAp85 in combina-
tion with p110. Cells were activated with CD3CD28 and we
measured CD28-associated PI3K activity in vitro. CD28 exhibited
a similar associated PI3K activity in both cases, suggesting that
CD28-bound p85 and p85 are in complex with p110 (Figure
2A). A faster PI3K activity association was observed in some cases
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Figure 2. Lower PKB activation in p85-deficient cells. (A,B) Jur-
kat cells were transfected with control, rHAp85, or rHAp85 in
combination with p110 vectors and incubated for 36 hours (A). T cells
were purified from Wild-type (WT) and p85/ and mice (B). Cells
were activated with CD3 CD28 antibodies (7 or 15 minutes) and
collected. PI3K activity was assayed in CD28 immunoprecipitates in
vitro. WB examined recombinant protein expression levels in cell
extracts. The histogram represents the mean plus or minus SD (n 3)
of the PIP3 signal inAUs. (C,D) T cells were purified from p85/ and
p85/ spleen and lymph node cell suspensions, then activated by
CD3, CD28, or CD3CD28 cross-linking (indicated). (C) Total cell
lysates were examined in WB using anti–pSer473-PKB, anti–pThr308-
PKB, anti–pThr389-p70S6K, or anti-PKB antibodies. Graphs show the
percentage of p-PKB or p-p70S6K signal compared with maximal
(with CD3CD28 at 5 minutes). (D) PKB was immunoprecipitated
from cell extracts and assayed in vitro using histone H2B as substrate.
Graphs were as in panel A. (E) Jurkat cells were transfected with
cDNA encoding the indicated p85 mutant forms, and 36 hours later
cells were activated as in panel A, and total extracts or CD28
immunoprecipitates resolved by SDS-PAGE and examined by WB
using anti-HA Ab. Vertical lines have been inserted to indicate a
repositioned gel lane. The graph shows the mean signal plus or minus
SD (AUs) of CD28-bound rp85 forms normalized for their expression
levels. Scheme showing the potential interaction domains of p85 and
CD28 and after activation. *P .05.
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in p85 cells, but the difference (n 3) was not statistically significant.
CD28 immunoprecipitates from CD3CD28-activated murine WT or
p85/ T cells also contained a similar associated PI3K activity
(Figure 2B), suggesting that p110 recruitment to CD28 is observed in
the presence or absence of p85.
PI3K assay might underestimate quantitative differences in
vivo; we thus examined the activation of the PI3K effectors PKB
and p70S6K upon stimulation of WT and p85/ T cells via CD3,
CD28, or both. p-p70S6K and p-PKB cell content was approxi-
mately one-third lower in p85/ T cells upon CD3 activation; in
contrast, CD28 activation resulted in p-p70S6K and p-PKB levels
that were approximately 60% lower in p85/ T cells than control
cells (Figure 2C), showing that a greater signaling defect is
observed upon stimulation of CD28. CD3CD28 activation also
yielded significantly lower levels of p-p70S6K and p-PKB in
p85/ cells (Figure 2C); we confirmed the lower PKB activity in
p85/ T cells in kinase assays (Figure 2D).
SH2 domains, and to lesser extent SH3 domains, are involved
in p85 binding to CD28
The Tyr170 region (M1 peptide) is Tyr phosphorylated after T-cell
activation; the C-terminal M2 region contains a phosphorylable Tyr
and a Pro-rich motif. Because pTyr residues bind to SH2 domains
and Pro-rich regions bind to SH3 domains, we tested the binding of
p85 to these regions. Previous studies showed that the CD28
Tyr170 region binds to p85 C-SH2 domain in vitro, whereas the
phosphorylated M2 region, containing Pro residues, binds both to
the C-SH2 and the SH3 p85 domains.40 We examined, in extracts
of CD3  CD28-activated Jurkat cells, the binding of CD28 to
p85 SH2-SH2 region, or to the SH3 region, or to a previously
described p65PI3K mutant encompassing the SH3, Bcr, and the
N-SH2 domains,42 in vivo. Cells were transfected with the different
HA-tagged p85 constructs; 36 hours later, the cells were activated
and the extracts immunoprecipitated with CD28; association to
p85 constructs was determined in WB using HA Ab. When
binding was normalized considering the expression levels, the
binding of wild-type p85 was lower than that observed with p85
fragments, suggesting that p85 folding partially masks the interac-
tion regions (Figure 2E). In the mutants, the greatest binding was
observed with the SH2-SH2 region, whereas binding to p65PI3K
mutant, which lacks the C-SH2 domain, was lower, suggesting that
the C-SH2 domain (or else both SH2 domains) is required for
binding to CD28 (Figure 2E). Moreover, the SH3 domain also
bound CD28, showing that, although to a lesser extent, SH3
binding to Pro residues also contributes to CD28-p85 association
(Figure 2E). Thus, p85 C-SH2 and SH3 domains participate in
p85 binding to CD28.
c-CBL and CBL-b preferentially associate with p85
CD28 binds to p85,36-40 which in turn associates with CBL-b and
c-CBL.18,44 Therefore, p85 might link CD28 and CBL. Because c-CBL
associates better with p85 than p85 in vitro,44 we tested whether p85
might also associate better than p85 with CBL proteins in vivo. We
measured CBL association with p85 and p85 in Jurkat T cells
transfected with rHAp85 or rHAp85. Although rHAp85 and
rHAp85 were expressed to a similar extent, CBL-b and c-CBL
immunoprecipitates contained more rHAp85 than rHAp85 (Figure
3A). p85 thus not only binds CD28 preferentially, but also shows
greater affinity for CBL-b and c-CBL, potentially acting as a bridge
between CD28 and the CBL. CBL contains Tyr-phosphorylated resi-
dues and a Pro-rich domain24 (Figure 3B bottom) that might bind SH2
and SH3 regions, respectively. To determine the p85 region involved in
association with CBL-b and c-CBL, cells were transfected with the
different HA-tagged p85 constructs; we immunoprecipitated the CBL
and determined association to different p85 constructs in WB using
HA Ab. Expression levels were as in Figure 2D. As in p85/CD28
association, p85 fragments showed greater binding than full-length
p85 to both CBLligases (Figure 3B). In addition, whereas CBL-b bound
preferentially to the SH3 domain and to the p65PI3K mutant (which
includes the SH3 domain), c-CBL bound preferentially to SH2-SH2 and
to p65PI3K (which includes the NSH2 domain), showing that the SH3
and NSH2 domains are likely the main regions of p85 binding to
CBL-b and c-CBL, respectively.
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Defective CBL regulation in p85-deficient T cells
CBL limits T-cell activation; indeed, defects in CBL-b down-
regulation yield T cells anergic.45-47 For this reason, one of the
critical actions of CD28 is to induce CBL-b down-regulation after
T-cell activation.15-20 Considering that p85 binds preferentially to
CD28 and the CBL, we examined whether p85 deletion impaired
CBL down-regulation. T cells from p85/ and p85/ mice
were activated in vitro with anti-CD3 or with anti-CD3anti-
CD28 antibodies; in control cells, CD3 activation reduced CBL-b
levels by 2 hours and reduction was more pronounced after
CD3  CD28 activation (Figure 4A). In contrast, CD3-induced
CBL-b reduction was significantly less pronounced in p85/
T cells and was unaffected by the presence of CD28 (Figure 4A).
Similarly, whereas in controls CD3 induced a moderate c-CBL
down-regulation at approximately 2 hours upon stimulation that
was enhanced in the presence of CD28Ab, neither CD3 nor
CD3CD28 reduced c-CBL levels in p85/ T cells (Figure 4A).
Although we detect CBL down-regulation defects upon CD3
stimulation this might also reflect CD28 signaling defects because
CD28/ mice show CD3-induced CBL down-regulation defects,16
implying that activation via TcR also involves CD28.
CBL down-regulation was also observed in vivo (Figure 4B).
p85/ and p85/ F5TCRTg mice were injected with antigenic
peptide. Antigenic peptide–loaded APCs activate T cells through
TcR and CD28.5 Primary antigen stimulation in vivo induced a
pronounced, transient reduction in CBL-b and c-CBL levels in
control mice T cells; p85/ T cells, however, showed a signifi-
cantly lower CBL-b and c-CBL down-regulation (Figure 4B).
Considering that PI3K/PKB pathway activation was lower in
p85/ T cells, we examined whether PI3K activity is required to
trigger CBL down-regulation. Jurkat T cells were activated in the
presence or absence of the PI3K inhibitors wortmannin (not shown) or
Ly294002 (Figure 4C). CD3 stimulation induced and CD3CD28
enhanced CBL down-regulation in Jurkat cells; however, PI3K inhibi-
tion did not block but moderately enhanced CBLdown-regulation, more
clearly that of CBL-b (Figure 4C). Because p85 deletion impairs CBL
down-regulation despite reduction of PI3K/PKB pathway activity, these
observations suggest that p85 controls CBLdown-regulation in a PI3K
activity–independent manner.
c-CBL and CBL-b regulate TCR down-regulation at late time
points.25,27,48 Considering that p85 links CD28 and the CBL, it was
possible that p85-deficient T cells exhibited defects in activation-
induced TCR down-regulation. Indeed, whereas CD3 cross-linking
induced a similar TCR down-regulation in WT and p85/ purified
T cells, CD3CD28–triggered TCR down-regulation was significantly
lower in p85/ T cells than in WT cells (Figure 5A), confirming the
signaling defects of CD28 in p85/T cells.
Nedd4 is not responsible for the CBL down-regulation defects
of p85/ mice
The CBL regulation defects of p85-deficient T cells might result
from defects in Nedd4 ubiquitin ligase, which targets c-CBL and
CBL-b for degradation.49 Anti-CD3 stimulation triggered Nedd4
expression at 72 hours in both p85/ and p85/ cells;
moreover, CD3  CD28 activation accelerated Nedd4 expression
in control cells but not in p85/ cells (Figure 5B). These
observations support the CD28 signaling defects in p85/
T cells, because whereas CD3 induced Nedd4 expression similarly
in control and p85/ T cells, CD28 failed to enhance Nedd4
expression in p85/ cells. In addition, these data show that
defective Nedd4 expression is not the cause of CBL down-
regulation defects because CBL levels decrease at 2 to 6 hours and
Nedd4 increases at approximately 36 hours after T-cell activation.
Increased expression of p85 enhances CBL and TCR
down-regulation
Because p85 deletion impaired CBL and TCR down-modulation,
we analyzed whether p85 overexpression might enhance these
processes. We expressed rHAp85 or rHAp85 in Jurkat cells.
Whereas in Jurkat cells transfected with empty vector, CD3CD28
stimulation triggered a reduction in CBL-b and c-CBL levels at 4 to
6 hours (Figure 5C), both rHAp85 and rHAp85 expression
resulted in a greater and more sustained CBL down-regulation,
more markedly in the case of p85. Moreover, in agreement with
the idea that p85 links CD28 to CBL, increased p85 expression,
and even more markedly that of p85, enhanced TCR down-
regulation compared with controls (Figure 5D). These observations
confirm the role of p85 as a molecule regulating TCR-CD28–
induced CBL down-regulation with a greater action of p85, which
might cooperate with p85 for this function.
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CD28 defective signaling in primary activation of p85/
T cells
APC-antigenic T-cell stimulation activates T cells in the context of
CD28 costimulation, which stabilizes the immunologic synapse
and prolongs TCR-induced signaling cascades.5-15 Because CD28
binds preferentially to p85, we analyzed the effect of p85
deletion on the signaling cascades triggered by APC-induced T-cell
activation in vivo using phosphoantibodies to analyze TyrK, PKC,
PKB, p38MAPK, and p44/42MAPK activation.
In agreement with the lower PKB activation in CD3  CD28–
stimulated p85/ T cells, primary antigenic stimulation in
p85/ F5TCRTg T cells induced a reduced pPKB content
compared with controls (Figure 5E). In addition, whereas at 15 to
30 minutes after stimulation, p44/42MAPK and p38MAPK activa-
tion occurred similarly in p85/ and p85/ F5TCRTg cells,
activation at 60 minutes was lower in p85/ T cells (Figure 5E).
As CD28 prologues signals induced by the TCR,5 these observa-
tions concur with the idea that CD28 signaling is defective in
p85/ cells. A similar defect was detected in TyrK stimulation
(not shown). PKC activation was greater in p85/ F5TCRTg
T cells than in controls (Figure 5E), in agreement with the higher
stability of c-CBL in these cells, as c-CBL enhances PLC/PKC
activation.24 Thus, a higher PKC activation, a less sustained MAPK
activation, and lower pPKB content were observed in primary-
stimulated p85/ T cells.
Reduced secondary immune response in p85-deficient mice
CD28-deficient T cells undergo an incomplete primary activation
resulting in a defective differentiation of activated T cells, which
become unresponsive on a secondary Ag challenge.7,8 As p85
binds to CD28 and regulates CD28 downstream signaling, we
examined whether p85 deficiency impaired secondary immune
responses. We first compared the primary and secondary immune
responses in p85/ and p85/ mice using as antigen Candida
albicans, which triggers mainly a CD4 cell response.50,51 The
primary response to C albicans was slightly higher in p85/
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Figure 5. p85 overexpression enhances CBL-b and TCR
down-regulation. (A) TCR down-modulation was measured by
flow cytometry in purified peripheral CD8 T cells from p85/
and p85/ F5TCRTg mice stimulated in vitro with CD3 or
CD3CD28 for the times indicated. TCR down-regulation was
estimated as the reduction in the mean fluorescence index of
TCR expression on stimulated CD8 versus nonstimulated
CD8 T cells (mean  SD, n  3). (B) Cells were activated as in
panel A, and Nedd4 levels were examined in WB. The graph
quantitates the mean plus or minus SD (n  3) of Nedd4 signal
relative to maximal levels (100%). (C,D) Jurkat T cells were
transiently transfected with empty vector or rHAp85 or . Cells
were activated as in panel A using CD3CD28 36 hours after
transfection and then collected. We analyzed CBL-b and c-CBL
levels in cell extracts by WB (C) or TCR down-modulation as in
panel A (D); MFI of TCR expression on stimulated CD4 versus
gated nonstimulated CD4 T cells (mean  SD, n  4; D).
Graphs (C) show CBL signal intensity in AUs (mean  SD,
n  3). (E) Purified peripheral CD8 T cells from p85/ and
p85/ F5TCRTg mice were stimulated in vitro with peptide-
pulsed APCs. Cell extracts were examined in WB (indicated). The
graphs represent the mean plus or minus SD (n  3) of the signal
for each of the proteins in 3 different assays, compared with the
maximal signal (100%) in WT cells at 15 minutes (pPKC), 30 min-
utes (pPKB), or 1 hour (p-p38, p-p44/42) and normalized in
comparison with loading controls (n  3). P values are shown for
the time points of maximal signal in WT cells (*P  .05).
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mice than in controls; in contrast, p85/ mice showed a
lower CD4 spleen and lymph node secondary immune response
(Figure 6A).
We also examined primary and secondary antigen-specific
immune responses. p85/ F5TCRTg and p85/ F5TCRTg
mice were immunized once with the NP366-374 influenza peptide
(primary) or challenged at day 0, and treated again 10 days later
(secondary). The primary response was moderately enhanced in
p85/ F5TCRTg mice but the secondary response was signifi-
cantly lower than in controls (Figure 6B). IL-2 partially restores
anergic cell proliferation.7-9 IL-2 addition enhanced T-cell prolifera-
tion in p85/ mice secondary response (Figure 6C), suggesting
that primary activated p85/ T cells behave as anergic cells.
Confirming a defective secondary response in p85/ mice, the
number of cells expressing the activation (CD25, CD69) and
memory (CD44high, CD62Llow) markers was significantly lower
upon secondary challenge in p85/ mice (Figure 6D). These data
show that p85 deficiency results in reduced CD4 and CD8
T-cell secondary immune responses.
CD28-mediated defects upon secondary p85/ T-cell
stimulation
We examined CBL down-regulation and intracellular pathways in
secondary responses. We immunized p85/ and p85/
F5TCRTg mice with the NP366-374 peptide, and 11 days later mice
were reinjected with the peptide; we examined CBL levels in vivo,
in extracts of cells collected at different times after injection. Basal
levels of CBL-b and c-CBL were moderately higher in p85/
T cells compared with controls, as in anergic cells46; in addition,
restimulation triggered a large CBL down-regulation in controls,
and a minor reduction in p85/ T cells (Figure 7A). For
intracellular signal analysis, mice were immunized with antigenic
peptide, and 11 days later purified T cells were restimulated in
vitro. PKB activation was reduced in p85/ T cells compared
with controls (Figure 7B); because CBL-b ubiquitinates p85 and
reduces PI3K activation,18,19 this concurs with the higher CBL-b
levels in p85/ cells. TyrK activation and p44/42MAPK activa-
tion were lower and delayed in p85/ T cells, as in anergic
cells.52 The basal activity of PKC was higher in p85/ T cells
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Figure 6. Reduced secondary responses in p85-deficient
mice. (A) p85/ and p85/ mice received an intraperitoneal
injection of heat-inactivated C albicans to induce a primary
response; 21 days later, some mice received an identical injection
to induce the secondary response. Splenocytes or lymph nodes
(LNs) were isolated and the cells analyzed by flow cytometry
using appropriate antibodies. The figure shows CD4 cell num-
bers at different times after injection (mean  SD; n  3). P val-
ues were calculated at day 5. (B) The NP366-374 influenza peptide
was injected into p85/ and p85/ F5TCRTg mice for a
primary response; injection was repeated after 11 days for the
secondary response. The figure shows CD8/V11 spleen cell
numbers at different times after injection (mean  SD, n  3).
™ indicates peptide injection. (C) For primary in vitro proliferation
assays, peripheral T cells from p85/ and p85/ F5TCRTg
mice were activated with peptide-pulsed APCs at different peptide
doses, alone or in the presence of IL-2 (10 U/mL). For secondary
immune response, mice received a peptide injection and were
killed after 10 days, when T cells were purified from spleen and
lymph nodes. T cells were then activated in vitro. [3H]thymidine
incorporation was measured at 48 hours (mean  SD, n  3).
↕ indicates the compared data for P value calculation (2 ng/mL
peptide). (D) p85/ and p85/ F5TCRTg mice received NP366-374
peptide at day 0 (™) to induce a primary IR; injection was repeated
at day 11 for the secondary IR. Mice were killed at different times
after peptide injection. T-cell activation/memory markers were
analyzed in the CD8/V11 population by flow cytometry. P val-
ues were calculated at 6 hours after secondary IR *P  .05).
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(Figure 7B), in agreement with the larger c-CBL levels in p85/
T cells, because c-CBL enhances PLC/PKC activity.21-24,27
Discussion
The presented observations show that p85 associates with
CD28 and regulates CD28 signaling delivery. p85 binds to
CD28, CBL-b, and c-CBL more efficiently than p85. This
function of p85 explains the reduced transmission of signals by
CD28 in p85/ T cells, including a lower PKB activation, as
well as a defective down-regulation of CBL-b and c-CBL.
Because PI3K/PKB activity is required for long-term survival,30
and CBL down-regulation by CD28 is required for activated
T cells to escape the anergy program,15 CBL and PKB defects
likely contribute to the impaired secondary immune response in
p85/ mice.
Effective activation of naive T cells requires a signal dependent
on TCR engagement by the peptide MHC and a secondary signal
provided by interaction between the antigen-presenting cell (APC)
and additional receptors in the T cell. CD28 provides a potent
costimulatory signal after engagement of its B7 ligands on the
APC. CD28 contributes to enhancing and prolonging the signals
induced by the TCR, synapse stability and long-time survival5-15;
these events regulate differentiation of primary stimulated T cells,
as activation of CD28/ T cells induces anergy.7-9 p85, the
regulatory subunit of PI3K, is one of the signaling molecules that
binds to CD28.36-40 We show that the p85 isoform exhibits
preferential binding to CD28 receptor compared with p85, as
examined in Jurkat cells expressing similar levels of rp85 or , or
in transformed and normal T cells analyzing endogenous p85 and
p85 subunits. Greater p85 binding to CD28 was confirmed in
vitro using purified p85 and CD28 peptides.
p85 binding to CD28 contributed to CD28-mediated early
signals as determined examining antigenic stimulation of normal
murine T cells, occurring in the context of CD28 stimulation,5-15
which resulted in lower PKB activation and less sustained MAPK
activation in p85/ T cells. The CD28 signaling defects in
p85/ T cells were confirmed examining activation of the PI3K
effectors PKB and p70S6K after CD3 or CD28 cross-linking,
which showed greater signaling defects upon CD28 activation than
after CD3 activation.
T-cell activation induces phosphorylation of CD28 on Tyr170
(on the M1 peptide, Figure 1). This phosphorylated site was
initially considered the main residue responsible for p85 binding.37
However, reconstitution of CD28-deficient mice with the trans-
genic Y170F-CD28 mutant rescued the T-cell anergy phenotype of
CD28/mice,53 arguing against the relevance of this residue or of
PI3K for anergy prevention. Nevertheless, whereas CD28 deletion
reduces PI3K activity after T-cell antigenic stimulation, the Y170F-
CD28 mutant did not reduce CD28-mediated PI3K activation,54
showing that PI3K binds to CD28 on a different site(s). There is a
second, noncanonical CD28 binding site for p85 at the C-terminus
of CD28.40 This motif is in the last 10 residues on CD28 (included
in peptide M2, Figure 1). Although in vitro the C-terminal CD28
region bound a lower amount of p85 regulatory subunit than the
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Figure 7. CBL down-regulation and pPKB defects upon secondary
stimulation of p85/ T cells. (A,B) We measured CBL expression
levels in antigen-experienced T cells; p85/ and p85/ F5TCRTg
mice were injected with the NP366-374 peptide; 11 days later both mice
groups were reinjected with the NP366-374 peptide, and CBL-b or c-CBL was
analyzed in WB at different times after injection (A). Alternatively, 11 days
after first priming, mice were killed and purified T cells were stimulated in
vitro with peptide-pulsed APCs for the times indicated. Cell extracts were
examined in WB using antibodies as indicated (B). Figures are representa-
tive of at least 3 experiments with similar results. Graphs in panel A show
the mean plus or minus SD (n  3) of CBL-b or c-CBL signal. Graphs in
panel B show the mean percentage plus or minus SD (n  3) of the signal
for each of the proteins, compared with the maximal signal in control cells
(100%) and normalized in comparison with loading controls (n  3).
P values are shown for the times of maximal signal (*P  .05).
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Tyr170-containing peptide, in vivo the scenario might differ, as
deletion of the C-terminal motif induced a 90% reduction on PI3K
activation and a defective CD28 costimulatory function,40 suggest-
ing that binding of PI3K to this motif is critical for CD28 function.
We showed that this region exhibits a high selectivity for p85
binding, pointing at binding of p85 to CD28 as a critical event for
CD28 costimulation.
p85 binding to CD28 also modulated CBL recruitment and
down-regulation. We show that rHAp85 bound better than p85
to CBL-b and c-CBL. p85 contribution to CD28-induced CBL
down-regulation was revealed examining antigen- or CD3CD28-
induced CBL down-regulation, which was markedly impaired in
p85/ T cells. We show that p85 regulated not only CBL-b
down-regulation, but also that of c-CBL, which was not previously
reported. A less marked defective down-regulation was also
observed upon CD3 stimulation, however, as CD3-induced CBL-b
down-regulation also involves CD28,16 this defect might be
secondary to the CD28 signaling defect. Alternatively, p85 might
also affect the signaling properties of TCR, Lck, LAT, and TRIM,
which also associate with p85 subunits.2,55,56 Nonetheless, compari-
son of the signaling defects of CD3- or CD28-stimulated p85/
T cells (Figure 2C) supports a greater contribution of p85 to
CD28-induced signal transduction. The requirement of p85 for
CD28-induced CBL down-regulation was not the consequence of
the reduced PI3K/PKB activity in p85/ T cells, because PI3K
activity was not required for CBL down-regulation.
We investigated the p85 regions responsible for association to
CD28, c-CBL, and CBL-b. The principal regions involved in binding to
CD28 were the SH2 domains, with a lower contribution of the SH3
domain. Because p65, a mutant including the BcR, SH3, and N-SH2
domains, did not bind CD28 efficiently, either the 2 SH2 domains are
required for p85 binding to CD28 or the p85 C-SH2 domain (which
is not present in p65) is critical for this interaction. Studies in vitro
using p85 domains support the contribution of C-SH2 and SH3
regions for the binding of CD28 to p85.40 As the SH3 regions are less
conserved between p85 and p85 ( 50% homology) than the
SH2-SH2 domains ( 82%), the greater p85 association might result
from the contribution of the SH3 domain.
In the case of the CBL, both c-CBL and CBL-b bound to p85
N-SH2 and SH3 regions; nonetheless, the relative contribution of these
domains was distinct. Whereas c-CBL exhibited a greater binding to
N-SH2 region, CBL-b bound preferentially to the SH3. Therefore, one
might envision a quadruple complex involving p85 C-SH2 domain
associating with CD28, the N-SH2 domain binding c-CBL, and the SH3
region bringing CBL-b into complex. More likely, as association of
CD28 and CBL to p85 was not exclusively dependent on single
domains, it is possible that several p85 molecules associated with the
T-cell synapse (through Lck, TCR, LAT, TRIM, etc) establish a more
complex network of interactions in which different p85 associate with
CD28, c-CBL, or CBL-b. We found that isolated domains bound better
to CD28, c-CBL, and CBL-b than the full-length p85, supporting the
idea that the binding of p85/p110 to receptor(s) or its activation induced
conformational changes facilitating subsequent interactions with p85.
p85//p85/ double-deficient mice developed a rare auto-
immune disorder similar to Sjo¨gren syndrome.57 T cells from these
mice exhibit a dramatic reduction in PI3K activation58 because p85
molecules protect p110 from degradation.59 Considering that PI3K
activity is required for regulatory T-cell differentiation,60 it is
possible that defective development of this population causes the
Sjo¨gren syndrome in p85//p85/ mice.
Together, we conclude that the p85 regulatory subunit of class IA
PI3K binds to CD28 more efficiently than to CD3, and with greater
affinity than p85, thereby regulating CD28-mediated downstream
signaling. In the absence of the p85, primary T-cell activation induces a
flawed PI3K pathway activation, and an impaired c-CBL and CBL-b
down-regulation, an effect that is independent of p85-associated PI3K
activity. These defects result in an impaired differentiation of activated
T cells, which are then unable to develop an efficient secondary immune
response. Considering the contribution of PI3K/PKB for long-term
T-cell survival30 as well as the need of CBL down-regulation for
CD28-mediated differentiation of activated T cells to functionally
competent memory T cells,15 we propose that impaired PKB activation
and CBL down-regulation in p85/ cells contributes to cause the
defective secondary responses in these mice, implying that p85 plays
an important role in CD28-mediated T-cell activation and differentiation.
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